Lifestyle Advice to Patients with Bladder Cancer: A National Survey of Dutch Urologists [0.03%]
荷兰泌尿科医师对膀胱癌患者的生话方式指导建议全国调查
Ivy Beeren,Carlos Koops,Antoine G van der Heijden et al.
Ivy Beeren et al.
Background: Not much is known about the extent to which urologists discuss lifestyle with patients with bladder cancer (BC), despite patients considering urologists as an important source of information and motivation. ...
Perioperative Use of ctDNA to Guide Treatment for Urothelial Carcinoma: The Future is Now [0.03%]
ctDNA指导尿路上皮癌手术治疗的未来已来
Tyler F Stewart,Healther Chalfin,Nicholas Simon et al.
Tyler F Stewart et al.
Muscle-invasive bladder cancer represents a potentially curable disease, yet often disease recurs and is ultimately fatal. Outcomes for patients with localized urothelial carcinoma are heterogeneous with some patients cured with surgery alo...
A Molecular Urine Assay to Detect Recurrences During Surveillance of High-Risk Non-Muscle Invasive Bladder Cancer [0.03%]
高危非肌层浸润性膀胱癌监测期间检测复发的分子尿检试验
Joep J de Jong,Florus C de Jong,Angelique C J van der Made et al.
Joep J de Jong et al.
Background: High-risk non-muscle invasive bladder cancer (HR-NMIBC) patients require long-term surveillance with cystoscopies, cytology and upper tract imaging. Previously, we developed a genomic urine assay for surveilla...
Effectiveness of Prolonged Antibiotic Prophylaxis in Radical Cystectomy: Preliminary Analysis of the MACS Randomized Clinical Trial [0.03%]
延长抗生素预防用药在根治性膀胱切除术中有效性的实效性研究：MACS随机临床试验的初步分析
Mariya Vladimirovna Berkut,Alexey Michaylovich Belyaev,Tatyana Yurievna Galunova et al.
Mariya Vladimirovna Berkut et al.
Background: Standard 24-hour antibiotic prophylaxis is widely employed to minimize the risk of infection complications within 30 days following radical cystectomy. However, a considerable variety of protocols and drug com...
Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer [0.03%]
膀胱癌三联疗法临床试验的入组条件和终点指标选择标准
Parminder Singh,Leslie Ballas,Guru P Sonpavde et al.
Parminder Singh et al.
Background: Trimodality therapy (TMT) is a viable option for muscle-invasive localized bladder cancer, providing an alternative to radical cystectomy in properly selected patients. The approval of novel therapeutics in di...
Sandeep Gurram,Nityam Rathi
Sandeep Gurram
Intravesical therapy is a critical component in the management of non-muscle-invasive bladder cancer (NMIBC), as it reduces rates of disease recurrence and progression. However, the presence of physiologic barriers in the urothelium reduces...
Mark S Soloway,Neil A Abrahams
Mark S Soloway
Piyush K Agarwal,Cora N Sternberg
Piyush K Agarwal
Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy [0.03%]
多中心分析淋巴结密度和分期对膀胱癌根治术患者特异性生存的影响
Erik J van Gennep,Francesco Claps,Peter J Bostrom et al.
Erik J van Gennep et al.
Background: Prognostic tools in pathological-node (pN) patients after radical cystectomy (RC) are needed. Objectives: To evaluate the p...
Factors Influencing Patient Decision-Making in the Treatment of Muscle-Invasive Bladder Cancer [0.03%]
肌层浸润性膀胱癌治疗中的患者决策因素分析
Avani Desai,Lucas Bouknight,Thomas Reed et al.
Avani Desai et al.
Background: In 2023, an estimated 82,290 individuals were diagnosed with bladder cancer in the United States. For muscle-invasive bladder cancer (MIBC), the American Urological Association recommends offering radical cyst...